Skip to content
Terazosin
Hytrin (terazosin) is a small molecule pharmaceutical. Terazosin was first approved as Hytrin on 1987-08-07. It is used to treat hypertension, prostatic hyperplasia, and urinary retention in the USA. The pharmaceutical is active against alpha-1B adrenergic receptor, alpha-1A adrenergic receptor, and alpha-1D adrenergic receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Terazosin hydrochloride
Tradename
Company
Number
Date
Products
HYTRINAbbott BiotherapeuticsN-019057 DISCN1987-08-07
4 products
HYTRINAbbott BiotherapeuticsN-020347 DISCN1994-12-14
4 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
terazosin hydrochlorideANDA2023-06-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypertensionEFO_0000537D006973I10
prostatic hyperplasiaEFO_0000284D011470N40
urinary retentionHP_0000016D016055R33
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04C: Drugs used in benign prostatic hypertrophy
— G04CA: Alpha-adrenoreceptor antagonists, benign prostatic hypertrophy
— G04CA03: Terazosin
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sleep initiation and maintenance disordersD007319F51.011——2—3
Hiv infectionsD015658EFO_0000764B20———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DementiaD003704F03——1——1
Psychophysiologic disordersD011602F45.9——1——1
SchizophreniaD012559EFO_0000692F20——1——1
DepressionD003863F33.9——1——1
Anxiety disordersD001008EFO_0006788F41.1——1——1
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.9——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTERAZOSIN
INNterazosin
Description
Terazosin is a member of quinazolines, a member of piperazines, a member of furans and a primary amino compound. It has a role as an antineoplastic agent, an antihypertensive agent and an alpha-adrenergic antagonist.
Classification
Small molecule
Drug classantihypertensives (prazosin type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC
Identifiers
PDB4O3F
CAS-ID63590-64-7
RxCUI37798
ChEMBL IDCHEMBL611
ChEBI ID9445
PubChem CID5401
DrugBankDB01162
UNII ID8L5014XET7 (ChemIDplus, GSRS)
Target
Agency Approved
ADRA1B
ADRA1B
ADRA1A
ADRA1A
ADRA1D
ADRA1D
Organism
Homo sapiens
Gene name
ADRA1B
Gene synonyms
NCBI Gene ID
147
Protein name
alpha-1B adrenergic receptor
Protein synonyms
adrenergic, alpha-1B-, receptor, Alpha-1B adrenoceptor, Alpha-1B adrenoreceptor
Uniprot ID
P35368
Mouse ortholog
Adra1b (11548)
alpha-1B adrenergic receptor (P97717)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,957 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6,579 adverse events reported
View more details